STAT3 and colorectal carcinoma: Considering that napabucasin has mostly been clinically used as a small-molecule STAT3 inhibitor with other conventional chemotherapeutic agents24, we also assessed the effects of various combinations of SC-43 or SC-78 with two first-line anti-mCRC drugs on the suppression of the self-renewal ability of the human CRC cells.